Literature DB >> 12076079

Expression of matrix metalloproteinases and their inhibitors in experimental retinal ischemia-reperfusion injury in rats.

Xu Zhang1, Taiji Sakamoto, Yasuaki Hata, Toshiaki Kubota, Toshio Hisatomi, Toshinori Murata, Tatsuro Ishibashi, Hajime Inomata.   

Abstract

Matrix metalloproteinases (MMPs) are endopeptidases that degrade the extracellular matrix (ECM) and are involved in the pathogenesis of retinal degeneration along with tissue inhibitors of metalloproteinases (TIMPs). The present study examined the expression and activation of two specific members of MMPs (MMP-2 and MMP-9) and their related inhibitors (TIMP-1 and TIMP-2) in an experimental retinal ischemia-reperfusion injury. Retinal ischemia-reperfusion injury (RIRI) was induced in adult rats with a ligation method. After one hour of ischemia and a varied reperfusion time (0, 3, 6, 12, 24, 48 and 76 hr), the rat eyes were enucleated. Retinal extracts underwent zymographic analysis to measure the activity of MMP-2/9. The activity of TIMP-1 and TIMP-2 was measured by reverse zymography. The protein level was examined by Western blot. Immunohistochemistry analysis was undertaken to assess the anatomical distribution of MMP-9 in the retina after RIRI. The gelatinolytic activity of ProMMP-2 (72 kDa) was increased markedly at 6 hr after RIRI. ProMMP-9 (92 kDa) was not detected in the control specimens, while it appeared at 3 hr, increased markedly at 6 hr, and reached maximal levels at 24 hr after RIRI. The gelatinolytic activity found ian retinal extracts was shown to be inhibited by 10 m M EDTA and activated in vitro by a known metalloproteinase activator (4-aminophenylmercuric acetate (APMA)), indicating that these enzymes were of the metalloproteinase class. By western blot, MMP-2/9 levels increased parallel to protein activity level in zymography. No corresponding increase in TIMP-1 and TIMP-2 protein activity and protein level was detected by reverse zymography and western blot. Elevated levels of MMP-9 and its distribution in retina were confirmed by immunohistochemistry. Expression of MMP-9 was detected in the inner and outer segments of rat retina, and the level becomes stronger at 24 hr after RIRI. In this study, ProMMP-2 and ProMMP-9 were expressed and increased significantly, but their inhibitors (TIMP-1 and TIMP-2) remained relatively unaltered in ischemic retina after RIRI in rats. These results suggest that MMP-2 and MMP-9 may play an important role in the pathomechanism of retinal ischemic injury. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076079     DOI: 10.1006/exer.2001.1152

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  10 in total

1.  Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment.

Authors:  Chrysanthos Symeonidis; Eudoxia Diza; Eleni Papakonstantinou; Efimia Souliou; George Karakiulakis; Stavros A Dimitrakos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-08-29       Impact factor: 3.117

2.  The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia.

Authors:  Nurit Mathalone; Nitza Lahat; Michal A Rahat; Keren Bahar-Shany; Yoram Oron; Orna Geyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-06       Impact factor: 3.117

3.  Mechanical force enhances MMP-2 activation via p38 signaling pathway in human retinal pigment epithelial cells.

Authors:  Xu Hou; Quan-Hong Han; Dan Hu; Lei Tian; Chang-Mei Guo; Hong-Jun Du; Peng Zhang; Yu-Sheng Wang; Yan-Nian Hui
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-10       Impact factor: 3.117

4.  Matrix metalloproteinases in the mouse retina: a comparative study of expression patterns and MMP antibodies.

Authors:  Lies De Groef; Lien Andries; Kim Lemmens; Inge Van Hove; Lieve Moons
Journal:  BMC Ophthalmol       Date:  2015-12-29       Impact factor: 2.209

5.  Effect of bradykinin on TGF-β1-induced retinal pigment epithelial cell proliferation and extracellular matrix secretion.

Authors:  Wenting Cai; Qingquan Wei; Qingyu Liu; Chengda Ren; Junling Liu; Ruiling Zhang; Mengmei He; Qianyi Wang; Yaru Du; Jing Yu
Journal:  BMC Ophthalmol       Date:  2016-11-10       Impact factor: 2.209

6.  Inhibition of Matrix Metalloproteinase 9 Enhances Rod Survival in the S334ter-line3 Retinitis Pigmentosa Model.

Authors:  Jung-A Shin; Hwa Sun Kim; Andrew Vargas; Wan-Qing Yu; Yun Sung Eom; Cheryl Mae Craft; Eun-Jin Lee
Journal:  PLoS One       Date:  2016-11-28       Impact factor: 3.240

7.  Decreased TNF Levels and Improved Retinal Ganglion Cell Survival in MMP-2 Null Mice Suggest a Role for MMP-2 as TNF Sheddase.

Authors:  Lies De Groef; Manuel Salinas-Navarro; Griet Van Imschoot; Claude Libert; Roosmarijn E Vandenbroucke; Lieve Moons
Journal:  Mediators Inflamm       Date:  2015-09-15       Impact factor: 4.711

8.  CD147 and matrix-metalloproteinase-2 expression in metastatic and non-metastatic uveal melanomas.

Authors:  Julia Lüke; Vlatka Vukoja; Tim Brandenbusch; Khaled Nassar; Jens Martin Rohrbach; Salvatore Grisanti; Matthias Lüke; Aysegül Tura
Journal:  BMC Ophthalmol       Date:  2016-06-03       Impact factor: 2.209

9.  Morroniside protects against cerebral ischemia/reperfusion injury by inhibiting neuron apoptosis and MMP2/9 expression.

Authors:  Guoyong Zeng; Weijiang Ding; Yin Li; Meiying Sun; Liying Deng
Journal:  Exp Ther Med       Date:  2018-07-17       Impact factor: 2.447

10.  Role of diagnostic factors associated with antioxidative status and expression of matrix metalloproteinases (MMPs) in patients with cancer therapy induced ocular disorders.

Authors:  Mahmood Rasool; Arif Malik; Muhammad Abdul Basit Ashraf; Mahwish Arooj; Asia Kiran; Sulayman Waquar; Ujala Ayyaz; Ayesha Zahid; Ahmad Zaheer; Abdul Jabbar; Maryam Zain; Amir Raza; Asim Mehmood; Tahira Batool Qaisrani; Zeenat Mirza; Mohammed Hussein Al-Qahtani; Sajjad Karim; Absarul Haque
Journal:  Saudi J Biol Sci       Date:  2018-08-12       Impact factor: 4.219

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.